Fresenius plans to cut 2,000 jobs globally at Kabi unit - Handelsblatt
Reuters
Published Jun 02, 2022 15:36
Updated Jun 02, 2022 16:21
(Reuters) - Healthcare group Fresenius SE (ETR:FREG) plans to cut 2,000 jobs globally at its generic drugs unit Kabi, or around 5% of the unit's workforce, as part of an efficiency programme, business daily Handelsblatt reported on Thursday.
In Germany, 250 jobs would be affected, the paper said.
Fresenius, which runs dialysis centers and hospitals, makes generic drugs and helps plan hospital construction projects, last year launched a group-wide cost cutting programme to become more competitive amid a declining share price over several years.
In February, it increased its cost savings target to at least 150 million euros ($160.70 million) per year after tax, up from a previous goal of more than 100 million euros.
"We are in an ongoing exchange with staff representatives about the possible consequences for employees," a spokesperson said on Thursday, adding that the outcome of such talks would be communicated as soon as possible.
($1 = 0.9334 euros)
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.